There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.
Type
HazMat fee for 500 gram (Estimated)
Excepted Quantity
USD 0.00
Limited Quantity
USD 15-60
Inaccessible (Haz class 6.1), Domestic
USD 80+
Inaccessible (Haz class 6.1), International
USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic
USD 100+
Accessible (Haz class 3, 4, 5 or 8), International
Gambogic acid activates caspases with EC50 of 0.78-1.64 μM and competitively inhibits Bcl-XL, Bcl-2, Bcl-W, Bcl-B, Bfl-1 and Mcl-1 with IC50 of 1.47, 1.21, 2.02, 0.66, 1.06 and 0.79 μM, respectively.
Gambogic Acid/藤黄酸 细胞实验
Cell Line
Concentration
Treated Time
Description
References
HCT-15P cells
0.0625-0.5 µM
7 days
Inhibited cell proliferation and induced apoptosis
Int J Oncol. 2015 Nov;47(5):1663-71.
Human prostate cancer cells (PC3)
100 nM
7-10 hours
Inhibited PC3 cell migration
Cancer Res. 2008 Mar 15;68(6):1843-50.
HCT-15R cells
0.0625-0.5 µM
9 days
Inhibited cell proliferation and induced apoptosis
Int J Oncol. 2015 Nov;47(5):1663-71.
Human prostate cancer cells (PC3)
400 nM
Inhibited PC3 cell proliferation
Cancer Res. 2008 Mar 15;68(6):1843-50.
HCT-15P cells
2 µM
6-24 hours
Induced G1 phase cell cycle arrest
Int J Oncol. 2015 Nov;47(5):1663-71.
FRT-Cx43 cells
1, 2, 5, 10 µM
10 minutes
To validate the inhibitory effect of D-GA on GJIC via Gap-FRAP assay, results showed that D-GA significantly inhibited fluorescence recovery.
Front Pharmacol. 2018 Jul 30;9:814.
LN215 cells
20 µM
10 minutes
To evaluate the inhibitory effect of D-GA on gap junctional intercellular communication (GJIC), results showed that D-GA significantly inhibited GJIC.
Front Pharmacol. 2018 Jul 30;9:814.
CT26
1 µM
12 hours
GA induces pyroptosis through the caspase-3/GSDME-dependent pathway, significantly reducing cell viability.
Cancers (Basel). 2022 Nov 9;14(22):5505.
HCT116
2 µM
12 hours
GA induces pyroptosis through the caspase-3/GSDME-dependent pathway, significantly reducing cell viability.
Cancers (Basel). 2022 Nov 9;14(22):5505.
Human prostate cancer PC3 cells
0.125–0.5 µM
12 hours (migration assay) or 24 hours (invasion assay)
To investigate the inhibitory effect of gambogic acid on TNF-α-induced migration and invasion of PC3 cells. Results showed that GA significantly inhibited TNF-α-induced migration and invasion of PC3 cells.
Acta Pharmacol Sin. 2012 Apr;33(4):531-41.
SW1990 cells
0.0, 0.5, 1.0, 2.0 µM
12, 24, 48 hours
To evaluate the effect of gambogic acid on the growth of pancreatic cancer cells. Results showed that gambogic acid effectively inhibited the growth of SW1990 cells in a dose- and time-dependent manner.
J Exp Clin Cancer Res. 2017 Aug 10;36(1):107.
MIA PaCa-2 cells
0.0, 0.5, 1.0, 2.0 µM
12, 24, 48 hours
To evaluate the effect of gambogic acid on the growth of pancreatic cancer cells. Results showed that gambogic acid effectively inhibited the growth of MIA PaCa-2 cells in a dose- and time-dependent manner.
J Exp Clin Cancer Res. 2017 Aug 10;36(1):107.
BxPC-3 cells
0.0, 0.5, 1.0, 2.0 µM
12, 24, 48 hours
To evaluate the effect of gambogic acid on the growth of pancreatic cancer cells. Results showed that gambogic acid effectively inhibited the growth of BxPC-3 cells in a dose- and time-dependent manner.
J Exp Clin Cancer Res. 2017 Aug 10;36(1):107.
PANC-1 cells
0.0, 0.5, 1.0, 2.0 µM
12, 24, 48 hours
To evaluate the effect of gambogic acid on the growth of pancreatic cancer cells. Results showed that gambogic acid effectively inhibited the growth of PANC-1 cells in a dose- and time-dependent manner.
J Exp Clin Cancer Res. 2017 Aug 10;36(1):107.
Human umbilical vein endothelial cells (HUVECs)
50-100 nM
12-16 hours
Inhibited HUVEC tube formation
Cancer Res. 2008 Mar 15;68(6):1843-50.
PPC1 cells
0.5, 1, 2, 5, 10 µM
20 hours
To evaluate the apoptosis-inducing effect of Gambogic Acid on PPC1 cells, results showed significant activation of caspase-3.
Mol Cancer Ther. 2008 Jun;7(6):1639-46.
Jurkat cells
0.1, 0.2, 0.5, 2, 5 µM
20 hours
To evaluate the apoptosis-inducing effect of Gambogic Acid on Jurkat cells, results showed significant induction of apoptosis.
Mol Cancer Ther. 2008 Jun;7(6):1639-46.
HL-60 cells
0.1, 0.2, 0.5, 2, 5 µM
20 hours
To evaluate the apoptosis-inducing effect of Gambogic Acid on HL-60 cells, results showed significant induction of apoptosis.
Mol Cancer Ther. 2008 Jun;7(6):1639-46.
CT26 cells
0, 25, 50 μg/mL
24 hours
Evaluate NPs@GA-induced apoptosis, showing NPs@GA has superior capacity to induce tumor cell apoptosis than free GA.
Mater Today Bio. 2025 Feb 24;31:101611.
SNU-668 cells
1.41 µM (IC50)
24 hours
To assess the cytotoxic effects of GA, it was found that GA induced similar cellular responses, including vacuolation and subsequent cell death.
Cell Death Dis. 2019 Feb 22;10(3):187.
SNU-449 cells
1.62 µM (IC50)
24 hours
To assess the cytotoxic effects of GA, it was found that GA induced similar cellular responses, including vacuolation and subsequent cell death.
Cell Death Dis. 2019 Feb 22;10(3):187.
NCI-H460 cells
2.35 µM (IC50)
24 hours
To assess the cytotoxic effects of GA, it was found that GA induced similar cellular responses, including vacuolation and subsequent cell death.
Cell Death Dis. 2019 Feb 22;10(3):187.
BxPC-3 cells
1.68 µM (IC50)
24 hours
To assess the cytotoxic effects of GA, it was found that GA induced similar cellular responses, including vacuolation and subsequent cell death.
Cell Death Dis. 2019 Feb 22;10(3):187.
MDA-MB 435S cells
1.33 µM (IC50)
24 hours
To assess the cytotoxic effects of GA, it was found that GA dose-dependently reduced cell viability and induced progressive cytoplasmic vacuolation and subsequent cell death.
Cell Death Dis. 2019 Feb 22;10(3):187.
MDA-MB 468 cells
2.35 µM (IC50)
24 hours
To assess the cytotoxic effects of GA, it was found that GA dose-dependently reduced cell viability and induced progressive cytoplasmic vacuolation and subsequent cell death.
Cell Death Dis. 2019 Feb 22;10(3):187.
MDA-MB 453 cells
1.5 µM (IC50)
24 hours
To assess the cytotoxic effects of GA, it was found that GA dose-dependently reduced cell viability and induced progressive cytoplasmic vacuolation and subsequent cell death.
Cell Death Dis. 2019 Feb 22;10(3):187.
NCI-H1299 cells
1 µM
24 hours
To evaluate the growth inhibitory and apoptosis-inducing effects of gambogic acid on NCI-H1299 cells. Results showed that gambogic acid significantly inhibited cell growth and induced apoptosis.
Br J Cancer. 2014 Jan 21;110(2):341-52.
NCI-H460 cells
4 µM
24 hours
To evaluate the growth inhibitory and apoptosis-inducing effects of gambogic acid on NCI-H460 cells. Results showed that gambogic acid significantly inhibited cell growth and induced apoptosis.
Br J Cancer. 2014 Jan 21;110(2):341-52.
A549 cells
3.5 µM
24 hours
To evaluate the growth inhibitory and apoptosis-inducing effects of gambogic acid on A549 cells. Results showed that gambogic acid significantly inhibited cell growth and induced apoptosis.
Br J Cancer. 2014 Jan 21;110(2):341-52.
Human umbilical vein endothelial cells (HUVECs)
40 nM
4 hours
Inhibited HUVEC invasion
Cancer Res. 2008 Mar 15;68(6):1843-50.
HCT-15R cells
2 µM
6-24 hours
Induced G1 phase cell cycle arrest
Int J Oncol. 2015 Nov;47(5):1663-71.
BxPC-3 cells
1 µM
24 hours
Gambogic acid induced autophagy in BxPC-3 cells, as evidenced by increased LC3-II expression and degradation of P62 protein.
Cancer Cell Int. 2019 Jan 5;19:7.
PANC-1 cells
1 µM
24 hours
Gambogic acid induced the conversion of LC3-I to LC3-II in PANC-1 cells, increased the number of autophagic vacuoles, and confirmed autophagy through the formation of acidic vesicular organelles (AVOs).
Cancer Cell Int. 2019 Jan 5;19:7.
HT-29 human colon cancer cells
0.00, 0.31, 0.62, 1.25, 2.50, 5.00 or 10.00 µM
24, 48 or 72 hours
Gambogic acid inhibited the proliferation of HT-29 cells in a dose- and time-dependent manner and induced apoptosis.
World J Gastroenterol. 2015 May 28;21(20):6194-205.
U266 cells
0.2 µM
4 hours
To assess the effect of GA on the PI3K/Akt/mTOR signaling pathway. The results showed that GA significantly inhibited the phosphorylation of Akt and mTOR in U266 cells under hypoxia.
Cancer Sci. 2014 Aug;105(8):1063-70.
Primary monocytes from CML patients
0.58–0.82 µM (IC50)
48 hours
Gambogic acid significantly decreased cell viability and induced apoptosis in primary monocytes from CML patients
Clin Cancer Res. 2014 Jan 1;20(1):151-63.
K562 cells
0.40 µM (IC50)
48 hours
Gambogic acid decreased cell viability in a dose-dependent manner, induced apoptosis and proliferation inhibition
Clin Cancer Res. 2014 Jan 1;20(1):151-63.
KBM5-T315I cells
0.35 µM (IC50)
48 hours
Gambogic acid decreased cell viability in a dose-dependent manner, induced apoptosis and proliferation inhibition
Clin Cancer Res. 2014 Jan 1;20(1):151-63.
KBM5 cells
0.32 µM (IC50)
48 hours
Gambogic acid decreased cell viability in a dose-dependent manner, induced apoptosis and proliferation inhibition
Clin Cancer Res. 2014 Jan 1;20(1):151-63.
Murine hepatocarcinoma H22 cells
0.4 µM
48 hours
To evaluate the effect of GA alone or in combination with proteasome inhibitors on cell viability. Results showed that GA alone had a weak inhibitory effect on cell viability, but when combined with proteasome inhibitors MG132 or MG262, the inhibitory effect was significantly enhanced.
Cancer Lett. 2011 Feb 28;301(2):221-8.
Human leukemia K562 cells
0.4 µM
48 hours
To evaluate the effect of GA alone or in combination with proteasome inhibitors on cell viability. Results showed that GA alone had a weak inhibitory effect on cell viability, but when combined with proteasome inhibitors MG132 or MG262, the inhibitory effect was significantly enhanced.
Cancer Lett. 2011 Feb 28;301(2):221-8.
SKBR3
0 to 10 µM
6 hours
Assess the effect of Gambogic Acid on Hsp90-dependent client proteins
Proc Natl Acad Sci U S A. 2016 Aug 16;113(33):E4801-9.
Human umbilical vein endothelial cells (HUVECs)
10 nM
7-10 hours
Inhibited HUVEC migration
Cancer Res. 2008 Mar 15;68(6):1843-50.
U266 cells
0.05–0.2 µM
8 hours
To evaluate the effect of GA on hypoxia-induced VEGF expression and secretion. The results showed that GA significantly inhibited VEGF expression and secretion in U266 cells under hypoxia.
Cancer Sci. 2014 Aug;105(8):1063-70.
U266 cells
0.025–6.4 µM
8 hours
To determine potential cytotoxic and anti-proliferative effects of GA. The results showed that treatment with GA at concentrations above 0.4μM led to a significant dose-dependent inhibition of U266 cell growth under normoxia and hypoxia.
Cancer Sci. 2014 Aug;105(8):1063-70.
CHO-TRVb-hTfR1 cells
0.3 μM
48 hours
To evaluate the cytotoxic effect of GA in cells expressing hTfR1, results showed that GA at 0.3 μM significantly inhibited cell proliferation and induced apoptosis.
Leukemia. 2009 Jan;23(1):59-70.
CHO-TRVb-neo cells
0.3 μM
48 hours
To evaluate the cytotoxic effect of GA in cells without TfR expression, results showed that GA at 0.3 μM significantly inhibited cell proliferation and induced apoptosis.
Leukemia. 2009 Jan;23(1):59-70.
HS-SULTAN cells
0.3 μM
48 hours
To evaluate the cytotoxic effect of GA on malignant hematopoietic cells, results showed that GA at 0.3 μM significantly inhibited cell proliferation and induced apoptosis.
Leukemia. 2009 Jan;23(1):59-70.
Human prostate cancer cells (PC3)
400 nM
Inhibited PC3 cell proliferation
Cancer Res. 2008 Mar 15;68(6):1843-50.
Human prostate cancer cells (PC3)
100 nM
7-10 hours
Inhibited PC3 cell migration
Cancer Res. 2008 Mar 15;68(6):1843-50.
Human umbilical vein endothelial cells (HUVEC)
40 nM
4 hours
Inhibited HUVEC invasion
Cancer Res. 2008 Mar 15;68(6):1843-50.
RAJI cells
0.3 μM
48 hours
To evaluate the cytotoxic effect of GA on malignant hematopoietic cells, results showed that GA at 0.3 μM significantly inhibited cell proliferation and induced apoptosis.
Leukemia. 2009 Jan;23(1):59-70.
RAMOS cells
0.3 μM
48 hours
To evaluate the cytotoxic effect of GA on malignant hematopoietic cells, results showed that GA at 0.3 μM significantly inhibited cell proliferation and induced apoptosis.
Leukemia. 2009 Jan;23(1):59-70.
U266 cells
0.3 μM
48 hours
To evaluate the cytotoxic effect of GA on malignant hematopoietic cells, results showed that GA at 0.3 μM significantly inhibited cell proliferation and induced apoptosis.
Leukemia. 2009 Jan;23(1):59-70.
IM-9 cells
0.3 μM
48 hours
To evaluate the cytotoxic effect of GA on malignant hematopoietic cells, results showed that GA at 0.3 μM significantly inhibited cell proliferation and induced apoptosis.
Leukemia. 2009 Jan;23(1):59-70.
HL-60 cells
0.3 μM
48 hours
To evaluate the cytotoxic effect of GA on malignant hematopoietic cells, results showed that GA at 0.3 μM significantly inhibited cell proliferation and induced apoptosis.
Leukemia. 2009 Jan;23(1):59-70.
JURKAT cells
0.3 μM
48 hours
To evaluate the cytotoxic effect of GA on malignant hematopoietic cells, results showed that GA at 0.3 μM significantly inhibited cell proliferation and induced apoptosis.
Leukemia. 2009 Jan;23(1):59-70.
SW1990 cells
0.0, 0.5, 1.0, 2.0 μM
12, 24, 48 hours
To evaluate the effect of gambogic acid on the growth of pancreatic cancer cells. Results showed that gambogic acid inhibited the growth of SW1990 cells in a dose- and time-dependent manner.
J Exp Clin Cancer Res. 2017 Aug 10;36(1):107.
MIA PaCa-2 cells
0.0, 0.5, 1.0, 2.0 μM
12, 24, 48 hours
To evaluate the effect of gambogic acid on the growth of pancreatic cancer cells. Results showed that gambogic acid inhibited the growth of MIA PaCa-2 cells in a dose- and time-dependent manner.
J Exp Clin Cancer Res. 2017 Aug 10;36(1):107.
BxPC-3 cells
0.0, 0.5, 1.0, 2.0 μM
12, 24, 48 hours
To evaluate the effect of gambogic acid on the growth of pancreatic cancer cells. Results showed that gambogic acid inhibited the growth of BxPC-3 cells in a dose- and time-dependent manner.
J Exp Clin Cancer Res. 2017 Aug 10;36(1):107.
PANC-1 cells
0.0, 0.5, 1.0, 2.0 μM
12, 24, 48 hours
To evaluate the effect of gambogic acid on the growth of pancreatic cancer cells. Results showed that gambogic acid inhibited the growth of PANC-1 cells in a dose- and time-dependent manner.
J Exp Clin Cancer Res. 2017 Aug 10;36(1):107.
Human umbilical vein endothelial cells (HUVEC)
50-100 nM
12-16 hours
Inhibited HUVEC tube formation
Cancer Res. 2008 Mar 15;68(6):1843-50.
Human umbilical vein endothelial cells (HUVEC)
10 nM
7-10 hours
Inhibited HUVEC migration
Cancer Res. 2008 Mar 15;68(6):1843-50.
SNU-668 cells
1.41 μM
24 hours
To assess the cytotoxic effects of GA on different types of cancer cells, it was found that GA induced similar cellular responses, including cytoplasmic vacuolation and subsequent cell death
Cell Death Dis. 2019 Feb 22;10(3):187.
SNU-449 cells
1.62 μM
24 hours
To assess the cytotoxic effects of GA on different types of cancer cells, it was found that GA induced similar cellular responses, including cytoplasmic vacuolation and subsequent cell death
Cell Death Dis. 2019 Feb 22;10(3):187.
NCI-H460 cells
2.35 μM
24 hours
To assess the cytotoxic effects of GA on different types of cancer cells, it was found that GA induced similar cellular responses, including cytoplasmic vacuolation and subsequent cell death
Cell Death Dis. 2019 Feb 22;10(3):187.
BxPC-3 cells
1.68 μM
24 hours
To assess the cytotoxic effects of GA on different types of cancer cells, it was found that GA induced similar cellular responses, including cytoplasmic vacuolation and subsequent cell death
Cell Death Dis. 2019 Feb 22;10(3):187.
MDA-MB 435S cells
1.33 μM
24 hours
To assess the cytotoxic effects of GA, it was found that GA dose-dependently reduced cell viability and induced cytoplasmic vacuolation and subsequent cell death
Cell Death Dis. 2019 Feb 22;10(3):187.
MDA-MB 468 cells
2.35 μM
24 hours
To assess the cytotoxic effects of GA, it was found that GA dose-dependently reduced cell viability and induced cytoplasmic vacuolation and subsequent cell death
Cell Death Dis. 2019 Feb 22;10(3):187.
MDA-MB 453 cells
1.5 μM
24 hours
To assess the cytotoxic effects of GA, it was found that GA dose-dependently reduced cell viability and induced cytoplasmic vacuolation and subsequent cell death
Cell Death Dis. 2019 Feb 22;10(3):187.
293T cells
1 µM
5 hours
Induced apoptosis, correlated with TfR expression levels
Proc Natl Acad Sci U S A. 2005 Aug 23;102(34):12095-100.
T47D cells
2 µM
15 minutes
Interfered with TfR internalization, increased cell surface TfR expression
Proc Natl Acad Sci U S A. 2005 Aug 23;102(34):12095-100.
Jurkat cells
5 µM
24 hours
Induced apoptosis, observed membrane blebbing by electron microscopy
Proc Natl Acad Sci U S A. 2005 Aug 23;102(34):12095-100.
Murine hepatocarcinoma H22 cells
0.4 µM
48 hours
GA as a single agent inhibited cell viability by less than 20%, but when combined with proteasome inhibitors MG262 or MG132, the inhibitory effect was significantly enhanced.
Cancer Lett. 2011 Feb 28;301(2):221-8.
Human leukemia K562 cells
0.4 µM
48 hours
GA as a single agent inhibited cell viability by less than 20%, but when combined with proteasome inhibitors MG262 or MG132, the inhibitory effect was significantly enhanced.
Cancer Lett. 2011 Feb 28;301(2):221-8.
Normal bone marrow mononuclear cells
0.5, 1, 2 μg/mL
24 hours
GA did not affect apoptosis in normal bone marrow cells at low concentration (<2.0 μg/mL).
Chin J Cancer Res. 2013 Apr;25(2):183-91.
JeKo-1 cells
0.0625-4 μg/mL
12, 24, 36 hours
GA significantly inhibited the growth of JeKo-1 cells in a dose- and time-dependent manner. The maximum GA-induced cytotoxity was evident at 36 hrs exposure to 4 μg/mL GA.
Chin J Cancer Res. 2013 Apr;25(2):183-91.
U937 cells
1.0 mg/L
24 hours
GA could correct the disrupted distribution of Nup88 in U937 cells and decrease the protein level by inhibiting gene transcription, leading to apoptosis.
Acta Pharmacol Sin. 2013 Feb;34(2):191-8.
Primary monocytes from CML patients
0.58–0.82 µmol/L (IC50)
48 hours
Gambogic acid significantly inhibited the cell viability of primary monocytes from CML patients with IC50 values of 0.58–0.82 µmol/L
Clin Cancer Res. 2014 Jan 1;20(1):151-63.
K562 cells
0.40 µmol/L (IC50)
48 hours
Gambogic acid decreased the viability of K562 cells in a dose-dependent manner with an IC50 value of 0.40 µmol/L
Clin Cancer Res. 2014 Jan 1;20(1):151-63.
KBM5-T315I cells
0.35 µmol/L (IC50)
48 hours
Gambogic acid decreased the viability of KBM5-T315I cells in a dose-dependent manner with an IC50 value of 0.35 µmol/L
Clin Cancer Res. 2014 Jan 1;20(1):151-63.
KBM5 cells
0.32 µmol/L (IC50)
48 hours
Gambogic acid decreased the viability of KBM5 cells in a dose-dependent manner with an IC50 value of 0.32 µmol/L
Clin Cancer Res. 2014 Jan 1;20(1):151-63.
Gambogic Acid/藤黄酸 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
C57BL/6 mice
Matrigel plug model
Subcutaneous injection
0.1-0.2 μM
Single injection, analyzed after 7 days
Inhibited angiogenesis in vivo
Cancer Res. 2008 Mar 15;68(6):1843-50.
KMF mice
H22 allograft model
Intraperitoneal injection
1 mg/kg (GA) and 2 mg/kg (MG132)
Once daily for 7 consecutive days
To evaluate the inhibitory effect of GA in combination with the proteasome inhibitor MG132 on tumor growth. Results showed that the combination treatment significantly inhibited tumor growth without apparent systemic toxicity.
Cancer Lett. 2011 Feb 28;301(2):221-8.
BALB/c nude mice
U266 cell xenograft model
Intravenous injection
2 mg/kg and 4 mg/kg
Once every other day for 14 days
To evaluate the anti-tumor and anti-angiogenic activity of GA in vivo. The results showed that GA significantly inhibited tumor growth and angiogenesis, and reduced the expression of HIF-1α and VEGF in tumor tissues.
Cancer Sci. 2014 Aug;105(8):1063-70.
BALB/c mice
CT26 tumor model
Intravenous injection
2 mg/kg and 8 mg/kg
Every two days for 11 days
GA significantly inhibited tumor growth by inducing GSDME-dependent pyroptosis and enhancing the antitumor immune response.
Cancers (Basel). 2022 Nov 9;14(22):5505.
Nude mice
KBM5 and KBM5-T315I xenograft model
Intraperitoneal injection
3 mg/kg/2 days
Every 2 days for 17 days
Gambogic acid significantly inhibited the growth of KBM5 and KBM5-T315I xenografts and reduced tumor weight
Clin Cancer Res. 2014 Jan 1;20(1):151-63.
SCID mice
A549 xenograft model
Intravenous injection
3.0 mg/kg
Every 2 days for 14 days
To evaluate the antitumor effects of gambogic acid combined with cisplatin on A549 xenograft models. Results showed that the combination therapy significantly inhibited tumor growth and induced apoptosis.
Br J Cancer. 2014 Jan 21;110(2):341-52.
BALB/c nude mice
MDA-MB 435S cell xenograft model
Intraperitoneal (i.p.) injections
4 or 8 mg/kg
Twice (day 0 and day 2), lasting for 14 days
To evaluate the in vivo antitumor effect of GA, it was found that GA dose-dependently reduced tumor size and cellular vacuolation was observed in tumor tissues.
Cell Death Dis. 2019 Feb 22;10(3):187.
Balb/c mice
CT26 colorectal cancer model
Peritumoral injection
5 mg/kg
Single injection, observed until day 21
Evaluate the antitumor effect of Gel-NPs@GA, showing significant tumor growth inhibition and immune cell infiltration.
Mater Today Bio. 2025 Feb 24;31:101611.
BALB/c nude mice
HT-29 cell xenograft model
Caudal vein injection
5, 10 or 20 mg/kg
Twice weekly for four weeks
Gambogic acid significantly inhibited the growth of HT-29 xenograft tumors in a dose-dependent manner.
World J Gastroenterol. 2015 May 28;21(20):6194-205.
BALB/c nude mice
Pancreatic cancer xenograft model
Intraperitoneal injection
8 mg/kg
Once every 3 days for 27 days
Combination treatment of gambogic acid and chloroquine significantly inhibited the growth of pancreatic cancer xenografts, reduced Ki-67 expression, and increased TUNEL-positive cells.
Cancer Cell Int. 2019 Jan 5;19:7.
Balb/c female nude mice
Xenograft tumor model of pancreatic cancer
Intraperitoneal injection
8 mg/kg (GA), 100 mg/kg (gemcitabine)
Once every 3 days for 26 days
To evaluate the synergistic effects of gambogic acid combined with gemcitabine in a xenograft tumor model of pancreatic cancer. Results showed that the combination treatment significantly repressed tumor growth with a tumor inhibition rate of 72.9%.
J Exp Clin Cancer Res. 2017 Aug 10;36(1):107.
Balb/c female nude mice
Xenograft tumor model of pancreatic cancer
Intraperitoneal injection
8 mg/kg
Once every 3 days for 26 days
To evaluate the synergistic effects of gambogic acid and gemcitabine combination therapy on the xenograft tumor model of pancreatic cancer. Results showed that the combination treatment significantly inhibited tumor growth.
J Exp Clin Cancer Res. 2017 Aug 10;36(1):107.
Nude mice
KBM5 and KBM5-T315I xenograft model
Intraperitoneal injection
3 mg/kg/2 days
Every 2 days for 17 days
Gambogic acid significantly inhibited the growth of both Bcr-Abl wild-type and Bcr-Abl-T315I mutant xenografts, with significantly reduced tumor weights compared to the vehicle-treated group
Clin Cancer Res. 2014 Jan 1;20(1):151-63.
BALB/c nude mice
MDA-MB 435S cell xenograft model
Intraperitoneal (i.p.) injections
4 or 8 mg/kg
Twice (day 0 and day 2), for 14 days
To evaluate the in vivo antitumor effect of GA, it was found that GA dose-dependently reduced tumor size and cellular vacuolation was observed in tumor tissues
Cell Death Dis. 2019 Feb 22;10(3):187.
KMF mice
H22 cell allograft model
Intraperitoneal injection
1 mg/kg
Once daily for 7 consecutive days
Combination treatment with GA and MG132 significantly inhibited tumor growth without apparent systemic toxicity.
搜索
HazMat Fee +
